We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
-4.08%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$230M
AUM Growth
-$30.3M
Cap. Flow
-$6.59M
Cap. Flow %
-2.86%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CERO
CERo Therapeutics
CERO
+$927K

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$7.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
1
Beam Therapeutics
BEAM
$2.65B
$113M 48.91%
4,540,132
-294,521
-6% -$7.52M
RAPP
2
Rapport Therapeutics
RAPP
$1.98B
$66.1M 28.73%
3,728,738
– –
ERAS icon
3
Erasca
ERAS
$6.66B
$27.7M 12.05%
11,055,554
– –
VERV
4
DELISTED
Verve Therapeutics
VERV
$11.3M 4.92%
2,008,809
– –
GOSS icon
5
Gossamer Bio
GOSS
$68.9M
$7.29M 3.17%
8,055,916
– –
OMIC
6
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$2.46M 1.07%
126,630
– –
QTTB icon
7
Q32 Bio
QTTB
$456M
$1.1M 0.48%
320,482
– –
UBX
8
DELISTED
Unity Biotechnology
UBX
$981K 0.43%
1,004,817
– –
CERO
9
DELISTED
CERo Therapeutics
CERO
$564K 0.24%
4,697
+3,975
+551% +$927K

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q4 2024 Portfolio in Review

As of Q4 2024, Arch Venture Management held 9 positions worth $230M, down 12% from $261M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2024: portfolio turnover was 0%. Arch Venture Management opened no new positions and made no exits, leaving the 9-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Arch Venture Management added most to CERo Therapeutics in Q4 2024, an estimated $927K increase.
  • Arch Venture Management's biggest Q4 2024 reduction was Beam Therapeutics, cutting an estimated $7.52M.
  • Arch Venture Management's ten largest holdings make up 100% of its $230M portfolio in Q4 2024.
  • Arch Venture Management opened 0 new positions and closed 0 in Q4 2024.
  • Arch Venture Management's portfolio value fell 12% quarter-over-quarter to $230M.

Based on Arch Venture Management's 13F filing for Q4 2024, filed 14 Feb 2025.